BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 17719275)

  • 1. Salmonella type III-mediated heterologous antigen delivery: a versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors.
    Panthel K; Meinel KM; Sevil Domènech VE; Trülzsch K; Rüssmann H
    Int J Med Microbiol; 2008 Jan; 298(1-2):99-103. PubMed ID: 17719275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant vaccines based on translocated effector proteins of Salmonella Pathogenicity Island 2.
    Husseiny MI; Wartha F; Hensel M
    Vaccine; 2007 Jan; 25(1):185-93. PubMed ID: 16887239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Salmonella typhimurium genes responsible for interference with peptide presentation on MHC class I molecules: Deltayej Salmonella mutants induce superior CD8+ T-cell responses.
    Qimron U; Madar N; Mittrücker HW; Zilka A; Yosef I; Bloushtain N; Kaufmann SH; Rosenshine I; Apte RN; Porgador A
    Cell Microbiol; 2004 Nov; 6(11):1057-70. PubMed ID: 15469434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SopB of Salmonella enterica serovar Typhimurium is a potential DNA vaccine candidate in conjugation with live attenuated bacteria.
    Nagarajan AG; Balasundaram SV; Janice J; Karnam G; Eswarappa SM; Chakravortty D
    Vaccine; 2009 May; 27(21):2804-11. PubMed ID: 19428891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salmonella pathogenicity island 2-mediated overexpression of chimeric SspH2 proteins for simultaneous induction of antigen-specific CD4 and CD8 T cells.
    Panthel K; Meinel KM; Domènech VE; Retzbach H; Igwe EI; Hardt WD; Rüssmann H
    Infect Immun; 2005 Jan; 73(1):334-41. PubMed ID: 15618170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterologous prime-boost immunizations with different Salmonella serovars for enhanced antigen-specific CD8 T-cell induction.
    Sevil Domènech VE; Panthel K; Winter SE; Rüssmann H
    Vaccine; 2008 Mar; 26(15):1879-86. PubMed ID: 18313813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid.
    Tartz S; Rüssmann H; Kamanova J; Sebo P; Sturm A; Heussler V; Fleischer B; Jacobs T
    Vaccine; 2008 Nov; 26(47):5935-43. PubMed ID: 18804138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-existing anti-Salmonella vector immunity prevents the development of protective antigen-specific CD8 T-cell frequencies against murine listeriosis.
    Sevil Domènech VE; Panthel K; Meinel KM; Winter SE; Rüssmann H
    Microbes Infect; 2007 Oct; 9(12-13):1447-53. PubMed ID: 17913544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic anti-tumor immunity against a murine fibrosarcoma triggered by the Salmonella type III secretion system.
    Panthel K; Meinel KM; Sevil Domènech VE; Geginat G; Linkemann K; Busch DH; Rüssmann H
    Microbes Infect; 2006 Aug; 8(9-10):2539-46. PubMed ID: 16919987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing hybrid Yersinia type III proteins.
    Rüssmann H; Igwe EI; Sauer J; Hardt WD; Bubert A; Geginat G
    J Immunol; 2001 Jul; 167(1):357-65. PubMed ID: 11418671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior protective immunity against murine listeriosis by combined vaccination with CpG DNA and recombinant Salmonella enterica serovar typhimurium.
    Berchtold C; Panthel K; Jellbauer S; Köhn B; Roider E; Partilla M; Heesemann J; Endres S; Bourquin C; Rüssmann H
    Infect Immun; 2009 Dec; 77(12):5501-8. PubMed ID: 19797070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant cytosolic delivery of two immunodominant listerial antigens by Salmonella enterica serovar typhimurium confers superior protection against murine listeriosis.
    Igwe EI; Geginat G; Rüssmann H
    Infect Immun; 2002 Dec; 70(12):7114-9. PubMed ID: 12438393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of fusogenic non-PC liposomes in elicitation of protective immune response against experimental murine salmonellosis.
    Ahmad N; Deeba F; Faisal SM; Khan A; Agrewala JN; Dwivedi V; Owais M
    Biochimie; 2006 Oct; 88(10):1391-400. PubMed ID: 16765503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An oral Salmonella vaccine promotes the down-regulation of cell surface Toll-like receptor 4 (TLR4) and TLR2 expression in mice.
    Eguchi M; Sekiya Y; Suzuki M; Yamamoto T; Matsui H
    FEMS Immunol Med Microbiol; 2007 Aug; 50(3):300-8. PubMed ID: 17451442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.
    Nishikawa H; Sato E; Briones G; Chen LM; Matsuo M; Nagata Y; Ritter G; Jäger E; Nomura H; Kondo S; Tawara I; Kato T; Shiku H; Old LJ; Galán JE; Gnjatic S
    J Clin Invest; 2006 Jul; 116(7):1946-54. PubMed ID: 16794737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of an intracellular-activated promoter for the generation of live Salmonella recombinant vaccines.
    Husseiny MI; Hensel M
    Vaccine; 2005 Apr; 23(20):2580-90. PubMed ID: 15780440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design of Salmonella-based vaccination strategies.
    Spreng S; Dietrich G; Weidinger G
    Methods; 2006 Feb; 38(2):133-43. PubMed ID: 16414270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic CD8 T-cell memory response to a Salmonella pathogenicity island 2 effector is restricted to Salmonella enterica encountered in the gastrointestinal mucosa.
    Jones-Carson J; McCollister BD; Clambey ET; Vázquez-Torres A
    Infect Immun; 2007 Jun; 75(6):2708-16. PubMed ID: 17403871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasion and destruction of a murine fibrosarcoma by Salmonella-induced effector CD8 T cells as a therapeutic intervention against cancer.
    Roider E; Jellbauer S; Köhn B; Berchtold C; Partilla M; Busch DH; Rüssmann H; Panthel K
    Cancer Immunol Immunother; 2011 Mar; 60(3):371-80. PubMed ID: 21132428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yersinia enterocolitica Yop mutants as oral live carrier vaccines.
    Leibiger R; Niedung K; Geginat G; Heesemann J; Trülzsch K
    Vaccine; 2008 Dec; 26(51):6664-70. PubMed ID: 18822332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.